Please login to the form below

Not currently logged in
Email:
Password:

advanced breast cancer

This page shows the latest advanced breast cancer news and features for those working in and with pharma, biotech and healthcare.

Lilly boosted by survival data for key growth drug Verzenio

Lilly boosted by survival data for key growth drug Verzenio

Chases Pfizer's Ibrance. Eli Lilly has the data readout it wanted to keep new breast cancer drug Verzenio firmly on a growth track as it chases after class leader Ibrance ... In the study, Verzenio (abemaciclib) – given alongside hormonal drug

Latest news

  • Keytruda scores in neoadjuvant triple negative breast cancer combo Keytruda scores in neoadjuvant triple negative breast cancer combo

    in patients with unresectable locally advanced or metastatic triple-negative breast cancer (TNBC) and whose tumours express PD-L1. ... as a neoadjuvant, or pre-surgical, segment of treatment for triple-negative breast cancer,” said Dr Roger Perlmutter,

  • Kisqali combination follows Verzenio onto Cancer Drugs Fund Kisqali combination follows Verzenio onto Cancer Drugs Fund

    advanced breast cancer. ... Ibrance and Kisqali gained NICE approval for first line treatment of hormone receptor (HR) positive, HER2 negative locally advanced or secondary breast cancer in November 2017, while Lilly’s drug only

  • Pfizer’s Talzenna cleared for breast cancer in Europe Pfizer’s Talzenna cleared for breast cancer in Europe

    Fourth to market aims to carve out niche. EU regulators have approved Pfizer’s PARP inhibitor Talzenna to treat patients with BRCA-mutated breast cancer, opening up another front in a ... The EMA has cleared the drug as a single-agent therapy for

  • FDA clears Novartis’ new breast cancer drug Piqray FDA clears Novartis’ new breast cancer drug Piqray

    Blockbuster potential for PI3K drug. Novartis has gained FDA approval for its PI3K inhibitor Piqray for advanced breast cancer, bucking the trend for the drug class in solid tumour therapy. ... Today's approval is expected to change the way we practice

  • Keytruda monotherapy fails in triple negative breast cancer Keytruda monotherapy fails in triple negative breast cancer

    Metastatic triple-negative breast cancer is an aggressive and challenging disease to treat, especially after progression on initial standard-of-care treatment,” said Dr. ... unmet medical need of patients with triple negative breast cancer.

More from news
Approximately 1 fully matching, plus 148 partially matching documents found.

Latest Intelligence

  • The handover: Pfizer reshapes itself for a new era The handover: Pfizer reshapes itself for a new era

    Innovative health revenue increased 4% to $8.47bn, lifted by sales of blood thinner Eliquis and breast cancer drug Ibrance outside the US, among others. ... In October the FDA also approved Talzenna (talazoparib), a new treatment of deleterious or

  • Deal Watch January 2018

    The incoming cash will be used by Immunomedics to fund its operations into 2020 including to progress development of sacituzumab govitecan in metastatic triple-negative breast cancer (TNBC), advanced urothelial cancer ... that is highly selective for HER2

  • Digital disruption Digital disruption

    Targeting advanced breast cancer the partners will combine real-world patient data and cognitive computing to ‘optimise cancer care and improve outcomes’. ... Next, they draw in the basic signalling pathways that can go wrong in cancer cells.

  • Deal Watch August 2016 Deal Watch August 2016

    The lead product is talazoparib, a PARP inhibitor, bought from BioMarin in phase III for treatment of BRCA mutated advanced breast cancer. ... This would complement Pfizer's palbococlib, launched in the US in February 2015, to treat HR+/HER2 metastatic

  • Pharma deals during July 2014 Pharma deals during July 2014

    investors. Seragon's focus is in hormone dependent cancers and specifically the development of its Selective Estrogen Receptor Degrader (SERD) platform of oral, small molecule therapeutics for breast and other cancers. ... The lead SERD compound, ARN-810,

More from intelligence
Approximately 0 fully matching, plus 9 partially matching documents found.

Latest from PMHub

More from PMHub
Approximately 0 fully matching, plus 5 partially matching documents found.

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Frontera Group

Welcome to Frontera Group where our agencies immerse you in the world of the patient...

Latest intelligence

The relevance of patient perspectives to value
Exploring the evolution of patient involvement in health technology assessment, and the role of the patient voice in market access....
How is the NHS Long-term Plan being put into action?
Steve How, Paul Midgley and Oli Hudson, of Wilmington Healthcare, explore some of the changes that have occurred since the plan was published...
real world studies
The evolution of real-world studies
How industry and regulators are using real-world data...

Infographics